-
First Public Notice for Environmental Impact Assessment of C Ray Therapeutics (Chengdu) Co., Ltd. Wenjiang R&D and Production Base Phase I Capability Upgrade Project
First Public Notice for Environmental Impact Assessment of C Ray Therapeutics (Chengdu) Co., Ltd. Wenjiang R&D and Production Base Phase I Capability Upgrade Project
넶12 2025-10-17 -
C-RAY Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [Lu-177]-BL-ARC001
October 9, 2025 – C-Ray Therapeutics (Chengdu) Co., Ltd. proudly congratulates its strategic partner, Biokin Pharmaceutical, on obtaining implied approval from the National Medical Products Administration (NMPA) for the clinical trial application of [Lu-177]-BL-ARC001 Injection. This milestone marks Biokin's first radiopharmaceutical and a Class 1 innovative biologic.
넶264 2025-10-09 -
EANM 2025 | C-Ray’s ²²⁵Ac Studies Featured as Top Oral Presentations at EANM 2025.
From October 4th to 8th, 2025, the global nuclear medicine community will gather for the highly anticipated annual event—the European Association of Nuclear Medicine (EANM) Annual Congress 2025—set to take place in Barcelona, Spain.
넶66 2025-09-30 -
On the Move, Shaping the Future: C-RAY Therapeutics Shines at Multiple Industry Events, See You at EANM 2025!
From the Greater Bay Area to Beijing-Tianjin-Hebei, from Zhangjiang Science City to the international stage in Hong Kong, this late summer and early autumn marked a productive journey of engagement for C-Ray. Each presentation reflected not only our technological expertise and strategic vision, but also our firm commitment to the long-term growth of China’s radiopharmaceutical industry.
넶19 2025-09-16
